Marc David  Benathen net worth and biography

Marc Benathen Biography and Net Worth

CFO of LifeMD
Marc Benathen brings to LifeMD more than 18 years of financial, strategy, direct-to-consumer, and operating leadership experience. He has served as LifeMD’s Chief Financial Officer since 2021.
Marc previously served as SVP and Chief Financial Officer for Blink Fitness, a national health and wellness brand, where he oversaw Finance, Accounting, Financial Operations, Procurement, Legal, and Member Services. Prior to this, Marc held several senior financial and operating positions with ANN, Inc, the then public company parent of Ann Taylor, LOFT, and Lou & Grey. Earlier in his career, Marc held finance and strategy positions of increasing responsibility across both publicly traded and high growth private equity owned companies.

Marc holds a BBA, Finance (Honors) from Baruch College.

What is Marc David Benathen's net worth?

The estimated net worth of Marc David Benathen is at least $90,483.12 as of August 18th, 2021. Mr. Benathen owns 17,953 shares of LifeMD stock worth more than $90,483 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Benathen may own. Additionally, Mr. Benathen receives an annual salary of $378,750.00 as CFO at LifeMD. Learn More about Marc David Benathen's net worth.

How old is Marc David Benathen?

Mr. Benathen is currently 43 years old. There are 7 older executives and no younger executives at LifeMD. Learn More on Marc David Benathen's age.

What is Marc David Benathen's salary?

As the CFO of LifeMD, Inc., Mr. Benathen earns $378,750.00 per year. Learn More on Marc David Benathen's salary.

How do I contact Marc David Benathen?

The corporate mailing address for Mr. Benathen and other LifeMD executives is 800 THIRD AVENUE SUITE 2800, NEW YORK NY, 10022. LifeMD can also be reached via phone at (866) 351-5907 and via email at [email protected]. Learn More on Marc David Benathen's contact information.

Has Marc David Benathen been buying or selling shares of LifeMD?

Marc David Benathen has not been actively trading shares of LifeMD within the last three months. Most recently, on Tuesday, November 30th, Marc David Benathen bought 7,831 shares of LifeMD stock. The stock was acquired at an average cost of $4.09 per share, with a total value of $32,028.79. Learn More on Marc David Benathen's trading history.

Who are LifeMD's active insiders?

LifeMD's insider roster includes Marc Benathen (CFO), Naveen Bhatia (Director), Corey Deutsch (Insider), Joseph DiTrolio (Director), Stefan Galluppi (CTO), Justin Schreiber (CEO), Bertrand Velge (Director), Happy Walters (Director), and Eric Yecies (General Counsel). Learn More on LifeMD's active insiders.

Are insiders buying or selling shares of LifeMD?

In the last twelve months, LifeMD insiders bought shares 1 times. They purchased a total of 3,000 shares worth more than $14,790.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 25,000 shares worth more than $163,000.00. The most recent insider tranaction occured on December, 2nd when CEO Justin Schreiber sold 25,000 shares worth more than $163,000.00. Insiders at LifeMD own 16.0% of the company. Learn More about insider trades at LifeMD.

Information on this page was last updated on 12/2/2024.

Marc David Benathen Insider Trading History at LifeMD

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Buy7,831$4.09$32,028.79View SEC Filing Icon  
8/18/2021Buy3,067$7.27$22,297.0917,953View SEC Filing Icon  
5/19/2021Buy1,416$8.91$12,616.56View SEC Filing Icon  
See Full Table

Marc David Benathen Buying and Selling Activity at LifeMD

This chart shows Marc David Benathen's buying and selling at LifeMD by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

LifeMD Company Overview

LifeMD logo
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Read More

Today's Range

Now: $5.04
Low: $4.76
High: $5.17

50 Day Range

MA: $5.38
Low: $4.08
High: $7.16

2 Week Range

Now: $5.04
Low: $3.99
High: $12.88

Volume

1,333,244 shs

Average Volume

742,021 shs

Market Capitalization

$218.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38